GC33

DRUG2 trials

Sponsors

Chugai Pharmaceutical, Hoffmann-La Roche

Conditions

Advanced or Metastatic HCCCarcinoma, Hepatocellular

Phase 1

A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

CompletedNCT00746317

Chugai PharmaceuticalAdvanced or Metastatic HCC

Start: 2008-09-30End: 2012-10-31Updated: 2012-10-17

Phase 2

A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

CompletedNCT01507168

Hoffmann-La RocheCarcinoma, Hepatocellular

Start: 2012-02-02End: 2015-08-20Updated: 2020-04-03

Related Papers

Case-control Indian buffet process identifies biomarkers of response to Codrituzumab.

2019-03-283 citations

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.

2016-04-1388 citations

Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168).

Journal of Clinical Oncology2014-05-2022 citations

Biomarker analysis of a randomized, placebo-controlled, double-blind, multicenter phase II trial of intravenous RO5137382/GC33 at 1600 mg Q2W in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma (HCC) (NCT01507168).

Journal of Clinical Oncology2014-05-201 citations